Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Quidel

This article was originally published in The Gray Sheet

Executive Summary

Quidel: Files 510(k) application with FDA for its QuickVue "one-step" Helicobacter pylori test. Designed for use with whole blood at point-of-care locations, the new product represents an advance over earlier versions of the test and would provide greater ease-of-use than competing products, the firm claims. Quidel also announces 510(k) clearance of its QuickVue Chlamydia test. Described as "a lateral flow immunoassay containing highly specific antibodies reactive to the Chlamydia organism," the test combines "fewer steps and faster results" and the "highest sensitivity among rapid tests" to allow physicians "to perform immediate, in-office detection and treatment," the firm says. Quidel submitted the premarket notification in January...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel